Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Brain : a Journal of Neurology
|
May 28, 2025
CSF proteomics of semorinemab Alzheimer's disease trials identifies cell-type specific signatures
Alyaa M Abdel-Haleem, Ellen Casavant, Balazs Toth, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
October 6, 2024
CSF complement proteins are elevated in prodromal to moderate Alzheimer's disease patients and are not altered by the anti-tau antibody semorinemab
Cosme Sandoval, Julie Lee, Balazs Toth, et al.
Neurology
|
August 29, 2023
Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet
Cecilia Monteiro, Balazs Toth, Flavia Brunstein, et al.
Science Translational Medicine
|
September 15, 2017
Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients
Joseph D Schonhoft, Cecilia Monteiro, Lars Plate, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
November 8, 2024
Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiology
Stephen P Schauer, Balazs Toth, Julie Lee, et al.
Journal of the American College of Cardiology
|
October 20, 2018
Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release
Brett W Sperry, Bryan A Reyes, Asad Ikram, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
June 29, 2026
Evaluation of CSF and plasma tau species as fluid surrogate candidates for tau PET in prodromal to moderate Alzheimer's disease
Julie Lee, Emily Olafson, Balazs Toth, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 25, 2025
Biomarkers
Julie Lee, Balazs Toth, Sandra Sanabria Bohorquez, et al.
Neurology and Therapy
|
February 27, 2021
Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-L<sub>Rx</sub> (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Teresa Coelho, Yukio Ando, Merrill D Benson, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Brain : a Journal of Neurology
|
May 28, 2025
CSF proteomics of semorinemab Alzheimer's disease trials identifies cell-type specific signatures
Alyaa M Abdel-Haleem, Ellen Casavant, Balazs Toth, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
October 6, 2024
CSF complement proteins are elevated in prodromal to moderate Alzheimer's disease patients and are not altered by the anti-tau antibody semorinemab
Cosme Sandoval, Julie Lee, Balazs Toth, et al.
Neurology
|
August 29, 2023
Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet
Cecilia Monteiro, Balazs Toth, Flavia Brunstein, et al.
Science Translational Medicine
|
September 15, 2017
Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients
Joseph D Schonhoft, Cecilia Monteiro, Lars Plate, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
November 8, 2024
Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiology
Stephen P Schauer, Balazs Toth, Julie Lee, et al.
Journal of the American College of Cardiology
|
October 20, 2018
Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release
Brett W Sperry, Bryan A Reyes, Asad Ikram, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
June 29, 2026
Evaluation of CSF and plasma tau species as fluid surrogate candidates for tau PET in prodromal to moderate Alzheimer's disease
Julie Lee, Emily Olafson, Balazs Toth, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 25, 2025
Biomarkers
Julie Lee, Balazs Toth, Sandra Sanabria Bohorquez, et al.
Neurology and Therapy
|
February 27, 2021
Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-L<sub>Rx</sub> (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Teresa Coelho, Yukio Ando, Merrill D Benson, et al.
Page
of 2